Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial

Chronic Intestinal Pseudo-obstruction Clinical Trial

Official title: Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Single Center, Randomized, Placebo Controlled, Double-blind Phase 2 Trial

Status Active, not recruiting

Clinical Trial Summary

The objective of the study is to investigate efficacy and safety of rifaximin (L-105) in patients with chronic idiopathic intestinal pseudo-obstruction(CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma

Clinical Trial Description

This is a placebo-controlled, randomized, double-blind, parallel group, comparative study, when patients with chronic idiopathic intestinal pseudo-obstruction(CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to the onset of systemic scleroderma, are administered rifaximin at 400 mg 3 times daily for 4 weeks. In addition, the time course of symptoms of the patients are to be confirmed for 8 weeks after the end of administration. ;

Related Conditions & MeSH terms

• Chronic Intestinal Pseudo-obstruction
• Intestinal Pseudo-Obstruction

• NCT number: NCT04118699
• Study type: Interventional
• Source: Yokohama City University
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: December 25, 2019
• Completion date: January 2022